"It's a paradigm shift." This is how Prof. Ulf Teichgräber, Director of the Institute of Diagnostic and Interventional Radiology at the University Hospital Jena, describes the improvement in communication with sponsors and CROs through the use of mint Lesion™. Together, Ms. Laura Graziani, study coordinator, Ms. Elisabeth Lammers, study assistant/MTRA, and Prof. Teichgräber describe their journey towards a successful clinical trial center that can now manage up to 40 clinical trials simultaneously.
Where results previously had to be painstakingly entered into Excel spreadsheets, mint Lesion™ has taken over the evaluation of all findings since its introduction in 2015, thus increasing the objectivity and validity of the study results.
Workflow optimization, increased efficiency and reduced errors in clinical trials
Related Resources
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer
For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…
Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging
How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?
Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion
Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…